Timing of PSA response to guide cessation of docetaxel in prostate cancer. This is an ASCO Meeting Abstract from the 2013 ASCO Annual Meeting I. This abstract does not include a full text component.

NEW YORK (Reuters Health) - Among men with good sexual function before treatment with low-dose brachytherapy for prostate cancer, erectile function is likely to remain good over the long term, ...

Pelvic second malignancy occurred twice as often after brachytherapy for prostate cancer as compared with radical prostatectomy, a large retrospective review showed. Second pelvic malignancy -- ...

The Prostate Cancer Institute of America was founded in 2022 by Ajay Bhatnagar, MD, and has since grown into a national network collaborating with ASCs to deliver low-dose rate brachytherapy (also ...

Approximately one in eight men will develop prostate cancer, which is the second-leading cause of cancer death in American men and typically affects patients who are 65 or older. Fortunately, the ...

“Many variations and intensifications of both EBRT and brachytherapy have been tested mainly in the higher and lower risk tiers of prostate cancer patients. Intermediate-risk prostate cancer patients ...